Mounjaro vs Saxenda: Cost, Access, and Clinical Results Compared

How the Two Drugs Work Differently

Mounjaro and Saxenda both activate GLP-1 receptors, but the similarity ends there. Saxenda is a pure GLP-1 receptor agonist dosed at 3 mg daily. Mounjaro is a dual GIP/GLP-1 receptor agonist given once weekly. That second receptor target changes the pharmacology significantly.

Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors simultaneously. GIP receptor activation appears to amplify the appetite-suppressing and metabolic effects beyond what GLP-1 alone achieves [1]. Preclinical and clinical data suggest the dual mechanism enhances insulin sensitivity, reduces glucagon secretion, and slows gastric emptying through complementary pathways. A 2022 analysis published in The Lancet confirmed that tirzepatide's dual agonism produced greater reductions in body weight and HbA1c than GLP-1-only agents across the SURPASS program [2].

Liraglutide, by contrast, is a well-characterized acylated GLP-1 analogue with a 13-hour half-life requiring daily dosing. It reduces appetite through hypothalamic GLP-1 receptor signaling and slows gastric emptying [3]. The SCALE program established its efficacy for weight management over a decade ago, giving clinicians years of real-world safety data that Mounjaro is still accumulating.

The practical difference for patients: one injection per week versus one per day. That alone shapes adherence. A 2023 retrospective analysis found that once-weekly GLP-1 RAs had 12-month persistence rates roughly 15-20 percentage points higher than daily formulations [4].

Weight Loss: Cross-Trial Comparison

Mounjaro produces substantially greater weight loss than Saxenda in indirect comparisons across their respective key trials. No direct head-to-head trial of tirzepatide versus liraglutide 3 mg has been published.

In the SURPASS-2 trial (N=1,879), patients with type 2 diabetes receiving tirzepatide 15 mg lost 12.4% of body weight at 40 weeks compared with 6.2% for semaglutide 1 mg [1]. In the SCALE Obesity and Prediabetes trial (N=3,731), liraglutide 3 mg produced 8.0% mean weight loss at 56 weeks versus 2.6% with placebo [5]. Even accounting for differences in trial populations (SURPASS-2 enrolled T2D patients; SCALE enrolled people with obesity or overweight with comorbidities), the magnitude gap is large.

The SURMOUNT-1 trial (N=2,539) tested tirzepatide specifically for obesity without diabetes. Participants on tirzepatide 15 mg lost 22.5% of body weight at 72 weeks [6]. That figure is nearly three times the SCALE result. Cross-trial comparisons carry real limitations. Different baseline BMIs, run-in periods, and diet/exercise counseling protocols make exact comparisons imperfect. But the pattern is consistent across every available dataset: tirzepatide produces more weight loss than liraglutide 3 mg by a wide margin.

A useful clinical heuristic: for patients needing less than 10% body weight reduction, Saxenda may be sufficient and easier to access. For those targeting 15% or more, tirzepatide-based therapy is the stronger pharmacological tool.

List Price and Out-of-Pocket Cost

Both drugs carry high list prices, but the numbers shift considerably once you factor in coupons, formulary tier, and pharmacy benefit design.

Mounjaro's wholesale acquisition cost runs approximately $1,023 per month for the diabetes indication. The obesity-indication brand, Zepbound, lists at roughly $1,060 per month. Eli Lilly's savings card program can reduce out-of-pocket costs to as low as $25 per month for commercially insured patients whose plans cover the drug [7]. Without insurance coverage, cash-pay patients face the full list price or can use direct-purchase programs. Lilly launched a direct-to-consumer vial option for Zepbound at roughly $399-$549 per month depending on dose in 2024 [8].

Saxenda's list price is approximately $1,349 per month. Novo Nordisk offers a savings card that may reduce costs to $25-$200 per month for eligible patients with commercial insurance. Saxenda has been on the market since 2014, which means more pharmacy benefit managers have established coverage policies and negotiated rebates. Some PBMs place Saxenda on preferred formulary tiers while excluding newer agents like Mounjaro/Zepbound entirely.

For uninsured or cash-pay patients, compounding pharmacies have filled some gaps. The FDA's drug shortage list has at various points included tirzepatide, temporarily permitting compounded versions at lower cost. Liraglutide went off the shortage list earlier, limiting compounding access. Patients should verify current shortage status through the FDA drug shortage database before assuming compounded versions are legally available.

The bottom line on cost: which drug is cheaper depends entirely on your specific insurance plan. A drug with a higher list price may cost less at the pharmacy counter if your insurer has negotiated a better rebate.

Insurance Coverage and Prior Authorization

Saxenda has a coverage advantage built on time. After more than a decade on the market, it appears on most major commercial formularies for weight management. Many insurers still classify obesity medications as "lifestyle" drugs and exclude them, but among plans that do cover anti-obesity pharmacotherapy, Saxenda is more likely to be listed than Mounjaro or Zepbound.

Mounjaro's coverage picture is split by indication. For type 2 diabetes, most commercial plans cover tirzepatide, though it may sit on a non-preferred tier requiring step therapy through metformin and possibly a sulfonylurea or SGLT2 inhibitor first. For obesity (branded as Zepbound), coverage is spottier. A 2024 employer benefits survey found that only 44% of large employers covered any GLP-1 for weight management, and among those, newer agents like tirzepatide faced more prior-authorization hurdles than established options [9].

Medicare Part D does not cover drugs prescribed solely for weight loss. This restriction affects both Saxenda and Zepbound. The Treat and Reduce Obesity Act has been reintroduced in Congress multiple times but has not passed as of May 2026. Medicaid coverage varies by state. As of early 2026, fewer than 15 state Medicaid programs cover anti-obesity medications, according to the Obesity Action Coalition [10].

Prior authorization for Mounjaro/Zepbound typically requires documentation of BMI 30 or above (or 27 with a weight-related comorbidity), evidence of failed lifestyle modification for 3-6 months, and sometimes failure of a first-line agent like phentermine or orlistat. Saxenda prior-authorization criteria tend to be similar but may be less stringent on step-therapy requirements given its longer formulary history.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has noted: "The biggest barrier to GLP-1 therapy for obesity is not clinical evidence. It is payer coverage. We have drugs that produce 15-20% weight loss, and most insurance plans still treat obesity as a cosmetic concern."

Side-Effect Profiles

Gastrointestinal side effects dominate both drugs. Nausea, vomiting, diarrhea, and constipation are the most common adverse events and the primary reason patients discontinue either medication.

In SURPASS-2, nausea occurred in 17-22% of tirzepatide-treated patients (dose-dependent) versus 18% with semaglutide 1 mg [1]. Discontinuation due to adverse events ran 4-7% across tirzepatide doses. In SCALE, nausea affected 40% of liraglutide 3 mg patients versus 15% on placebo, and 9.9% discontinued due to GI side effects [5]. The higher nausea rate with Saxenda likely reflects its daily dosing. Each injection re-triggers the GLP-1 receptor activation cycle.

Mounjaro's once-weekly dosing provides steadier drug levels, which may explain its comparatively lower GI side-effect rates despite producing more weight loss. Both drugs carry a boxed warning about medullary thyroid carcinoma risk based on rodent studies. Neither has shown a confirmed signal for thyroid cancer in humans, but both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [11].

Pancreatitis has been reported with both agents at low rates. The FDA's post-marketing surveillance data has not identified a statistically significant increase in pancreatitis risk with either drug beyond what is expected in the obese population at baseline.

Injection-site reactions are generally mild with both drugs. Saxenda uses a smaller needle gauge familiar to patients who have used insulin pens. Mounjaro's autoinjector device has received positive usability ratings in patient surveys, though some patients report discomfort at higher doses when injection volume increases.

Dosing, Titration, and Convenience

Saxenda requires a 4-5 week titration: 0.6 mg daily for week one, increasing by 0.6 mg each week until reaching the maintenance dose of 3 mg daily. Patients inject once daily at any time, with or without food. The pen is pre-filled and does not require reconstitution.

Mounjaro starts at 2.5 mg once weekly for four weeks, then increases to 5 mg weekly. Dose escalation can continue in 2.5 mg increments every four weeks up to a maximum of 15 mg weekly, based on tolerability and clinical response [12]. The longer interval between dose increases may reduce GI side effects during titration.

The convenience difference is stark. Seven injections per week versus one. For patients with needle aversion, injection fatigue, or busy schedules, Mounjaro's once-weekly regimen is a meaningful quality-of-life advantage. A 2023 patient preference study published in Diabetes, Obesity and Metabolism found that 87% of patients preferred weekly over daily injectable GLP-1 therapy when efficacy was held constant [13].

Storage requirements are similar. Both drugs require refrigeration (36-46°F) before first use. Both can be kept at room temperature (up to 86°F) for a limited period after first use: 21 days for Mounjaro, 30 days for Saxenda.

Who Should Choose Which Drug

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends selecting anti-obesity medications based on expected efficacy, patient comorbidities, side-effect profile, cost, and patient preference [14]. There is no single correct choice for every patient.

Saxenda may be the better fit for patients whose insurance covers it but excludes tirzepatide, those who need modest weight loss (5-10%), patients already familiar and comfortable with daily injection routines from insulin therapy, and those who prefer a drug with a longer post-marketing safety track record.

Mounjaro or Zepbound is the stronger option for patients targeting 15% or greater body weight reduction, those with concurrent type 2 diabetes (where tirzepatide's glucose-lowering effects add value), patients who want once-weekly dosing, and those whose insurance covers it or who can access Lilly's direct-purchase vial program.

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, has stated: "We now have a range of GLP-1-based therapies. The conversation with patients should start with goals and access, not with which drug produced the biggest number in a trial."

Both drugs require ongoing use to maintain weight loss. The STEP-1 extension and SCALE maintenance studies showed significant weight regain within one year of discontinuation [15]. Patients choosing either Mounjaro or Saxenda should plan for long-term therapy and verify that their coverage will support continued access beyond the first authorization period.

Switching Between Mounjaro and Saxenda

No published clinical trial has studied a direct switch protocol from tirzepatide to liraglutide 3 mg or vice versa. In practice, clinicians manage transitions based on general GLP-1 RA switching principles.

When switching from Saxenda to Mounjaro, most prescribers discontinue liraglutide and start tirzepatide at 2.5 mg weekly the following week. No washout period is required. The different receptor profile (dual versus single agonist) means patients may experience a new round of GI side effects during the transition even if they tolerated Saxenda well.

Switching from Mounjaro to Saxenda (typically driven by insurance formulary changes or cost) requires starting Saxenda's full titration schedule from 0.6 mg daily. Skipping titration steps increases nausea and vomiting risk substantially. Patients should expect a period of reduced efficacy during the 4-5 week titration compared to what they experienced on maintenance-dose tirzepatide.

The American Association of Clinical Endocrinology (AACE) 2024 obesity algorithm recommends documenting the clinical rationale for any anti-obesity medication switch and obtaining prior authorization for the new agent before discontinuing the current one to avoid treatment gaps.